News & Updates

Prostate cancer patients who are also smokers have a greater risk of death, an effect that is further exacerbated by obesity, reports a recent study.

In patients with resectable non-small-cell lung cancer (NSCLC), neoadjuvant nivolumab in combination with platinum-based chemotherapy significantly improves event-free survival (EFS) and shows a trend towards better overall survival (OS) vs chemotherapy alone, without impeding the feasibility of surgery or increasing adverse events (AEs), according to results of the phase III CheckMate 816 trial.

The combination of ipilimumab and nivolumab may provide a progression-free survival (PFS) benefit in patients with metastatic or unresectable melanoma who did not respond to anti-PD-1/anti-PD-L1 therapy, according to a small study presented at AACR 2022.

Short-term concurrent androgen deprivation therapy (ADT) results in markedly worse overall survival (OS) among intermediate-risk (IR) prostate cancer patients on dose-escalated intensity modulated radiation therapy (IMRT) with daily image-guided RT, reveals a study.

In patients with multiple myeloma (MM), a higher allostatic load (AL) seems to be an important predictor of worse overall survival (OS), a recent study has found.

The KRAS^G12C inhibitor sotorasib has demonstrated durable efficacy in patients with locally advanced or metastatic KRAS^G12C-mutated non-small-cell lung cancer (NSCLC), with 2-year overall survival (OS) reported in one-third of patients in the CodeBreaK 100 trial.

The addition of the monoclonal anti-interleukin-1β antibody canakinumab to the standard of care (SoC) regimen of platinum doublet chemotherapy and pembrolizumab in the first-line setting did not improve progression-free survival (PFS) or overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC), results of the phase III CANOPY-1 trial showed.